“Gamma Delta T Cell Cancer Therapy Market & Clinical Trials Forecast 2028” Report Highlights:
- Commercialization Market Potential After Market Launch: > USD 4 Billion
- Insight on Key Drugs In Research & Development
- Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight
- Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies
- Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type
- Adopted Approaches for Gamma Delta T Cell Therapy
In addition to alpha beta T lymphocytes and B lymphocytes, research studies have identified gamma delta T lymphocytes which form an integral part of adaptive immune system. These novel cells act as interface between adaptive and innate immunity and play a vital role in maintaining hemostasis. Further genetic analysis revealed that gamma delta T cells are capable of eradicating tumor cells and triggers systemic response via the adaptive immune system, without harming healthy cells. The promising anti-tumor response of gamma delta T cells has gained considerable attention as an attractive tool for adoptive cancer immunotherapy.
Scientists have adopted two novel approaches including bispecific antibodies and chimeric antigen receptor (CAR) T cell therapy for utilizing gamma delta T cells for the management of cancer and other viral infections. The majority of ongoing clinical trial constitutes CAR gamma delta T cell therapy which is mainly attributed to the promising response of CAR T cell therapy in the management of hematological malignancies and the encouraging response of gamma delta T cells in overcoming the adverse events associated with conventional T cells. However, bispecific antibodies or dual targeting moieties recognizing gamma delta T cell from one receptor and tumor associated antigen from other receptor is also gaining popularity among researchers. Despite significant interest from researchers, the gamma delta T cell therapy is currently present at initial stages of clinical development.
Although no gamma delta T cell therapy has been approved by regulatory bodies, there are more than 100 ongoing clinical trials which are evaluating the role of these cells in the management of several cancers including hematological malignancies, solid cancers, and others. Several pharmaceutical giants have developed a robust pipeline of gamma delta T cell therapy products which have shown encouraging initial results. For instance in 2021, Adicet Bio announced positive interim clinical data for its first ever allogeneic, off-the shelf gamma delta CAR T cell therapy. Apart from this, several preclinical studies are also evaluating the role of gamma delta T cells in other non-oncological conditions including HIV, malarial infection, Crohn disease, COVID-19, and others.
The pharmaceutical industry is currently more inclined in developing novel therapy for the management of cancer. The current generation of cancer therapy is associated with several challenges including manufacturing issues, limited therapeutic benefits, and sky high price. The promising results of gamma delta T cell therapy over conventional cancer therapies have also increased the investment in this sector. In addition, there is increasing trend of collaboration or partnership among pharmaceutical companies which further boosts the growth of market.
For instance in 2020, Lava Therapeutics entered into a research and license agreement with Jannsen Biotech to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. The collaboration was facilitated by Johnson & Johnson Innovation. Apart from this, Twist Bioscience Corporation and Adicet Bio also collaborated to accelerate the discovery of gamma delta T cell therapies against five undisclosed targets. The companies will work together to engineer immune cells with fully human chimeric antigen receptors (CARs) and T-cell receptors (TCRs) directed to disease-specific cell surface antigens. This precise and targeted engagement is designed to provide a superior potential to facilitate recognition and killing of tumor cells. Apart from his, several other companies including Gamma Delta Therapeutics, TC Biopharma, Kiromic Biopharm, Gadeta, Adapate, and Acepodia are also increasingly investing in this sector.
As per our report findings , the global gamma delta T cell therapy is expected to surpass US$ 4 Billion by 2028, which is mainly attributed to increase in prevalence of cancer and unmet need of targeted therapies in its management. The report provides in depth analysis on the ongoing clinical trials in the market along with the future opportunity of gamma delta T cells in different cancers.